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Abstract 25 
Despite the substantial body of research investigating the use of liposomes, niosomes and 26 
other bilayer vesicles for drug delivery, the translation of these systems into licensed products 27 
remains limited. Indeed, recent shortages in the supply of liposomal products demonstrate 28 
the need for new scalable production methods for liposomes. Therefore, the aim of our 29 
research has been to consider the application of microfluidics in the manufacture of 30 
liposomes containing either or both a water soluble and a lipid soluble drug to promote co-31 
delivery of drugs.  For the first time, we demonstrate the entrapment of a hydrophilic and a 32 
lipophilic drug (metformin and glipizide respectively) both individually and in combination 33 
using a scalable microfluidics manufacturing system. In terms of the operating parameters, 34 
the choice of solvents, lipid concentration and aqueous:solvent ratio all impact on liposome 35 
size with vesicle diameter ranging from ~90 to 300 nm. In terms of drug loading, microfluidics 36 
production promoted high loading within  ~100 nm vesicles for both the water soluble drug 37 
(20 - 25% of initial amount added) and the bilayer embedded drug (40 – 42% of initial amount 38 
added) with co-loading of the drugs making no impact on entrapment efficacy. However, co-39 
loading of glipizide and metformin within the same liposome formulation did impact on the 40 
drug release profiles; in both instances the presence of both drugs in the one formulation 41 
promoted faster (up to 2 fold) release compared to liposomes containing a single drug alone.  42 
Overall, these results demonstrate the application of microfluidics to prepare liposomal 43 
systems incorporating either or both an aqueous soluble drug and a bilayer loaded drug.  44 
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1. Introduction 45 
Since their discovery in the 1960s (Bangham and Horne, 1964) and first application as drug 46 
delivery systems (Gregoriadis and Ryman, 1971), liposomes continue to offer new 47 
opportunities to improve the delivery and targeting of a range of therapeutic agents, from 48 
small molecules through to large biologicals. Furthermore, thanks to the research of AT 49 
Florence, who first demonstrated the ability to formulate bilayer vesicles from non-ionic 50 
surfactants, also known as non-ionic surfactant vesicles (NISVs) or niosomes (e.g. (Azmin et 51 
al., 1985; Baillie et al., 1985; Uchegbu and Florence, 1995)), a range of other bilayer vesicles 52 
have been developed. For example, vesicles built from surfactant polymers (e.g. 53 
polymersomes (Okada et al., 1995)), cationic systems which can electrostatically bind DNA 54 
(e.g. lipoplexes (Felgner et al., 1987)), vesicles incorporating bile salts to improve stability (e.g. 55 
bilosomes (Conacher et al., 2001)), or virus components (e.g. virosomes (Almeida et al., 56 
1975)). 57 
However, despite the substantial body of research investigating their use, the translation of 58 
these bilayer vesicles into licensed products remains limited, with approximately 15 products 59 
currently approved, including the first generic version of liposomal doxorubicin hydrochloride 60 
(Lipodox). The approval of Lipodox by the US Food and Drug Administration (FDA) in priority 61 
review was aimed to ensure that provision of doxorubicin hydrochloride liposomal injection 62 
was not interrupted, despite supply shortages of the liposomal doxorubicin product Doxil 63 
(licensed for the treatment of ovarian cancer). These supply shortages started in 2011 when 64 
the FDA identified issues in the manufacturing site responsible for the production of Doxil.  65 
In general, the manufacturing considerations of liposomal products can be considered a 66 
notable hurdle, given the cost and relative complexity of their production. In terms of 67 
characteristics and attributes to be considered for liposome drug products, these range from 68 
the physico-chemical properties of all the individual components (include the drug substance, 69 
the lipids and non-lipid components of the system) and the resulting liposomal product. Given 70 
that the pharmacological, toxicological and pharmacokinetic properties of the drug can be 71 
dictated by the liposomal product, quantification of the amount of drug incorporated and 72 
retained within the system must be defined. Furthermore, given that the pharmacokinetic 73 
profiles of the liposomal products are dictated by the liposomal physicochemical properties 74 
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(e.g. size, morphology, surface characteristics, liposome structure and integrity, net charge 75 
etc.), these should be characterised and defined. Indeed these are key critical quality 76 
attributes of a liposomal product and are often dictated by the method of manufacture. 77 
Given the recent issues seen in the manufacture of liposome products and to facilitate the 78 
transition of more liposomal products from bench to clinic, it is important that new, low-cost 79 
and scalable manufacturing methods for liposomes and their related systems are developed.  80 
At the basic level, there are two main ways of forming liposomes: either to produce large 81 
vesicles and then employ size reduction methods (e.g. homogenisation, microfluidisation, 82 
high-sheer mixing and sonication), or alternatively bottom up methods, which promote the 83 
formation of small vesicles from individual lipid monomers. Whilst the production of large 84 
vesicles followed by size reduction is the commonly adopted method at the laboratory scale, 85 
such methods of liposome manufacture lack industrial scalability and encapsulation 86 
efficiencies are usually low.  87 
In contrast, methods that exploit fluidic control to build liposomes from the bottom-up tend 88 
to offer more industrial applicability. For example, the ethanol injection method was the first 89 
one reported in the 1970s by Batzri and Korn (Batzri and Korn, 1973). Using this method, the 90 
formation of liposomes results from the rapid injection of lipids dissolved in ethanol into an 91 
aqueous buffer stream; the precipitation of the lipids leads to the formation of vesicles. This 92 
method is relatively simple and easy to scale, with the process considerations including the 93 
solubility of the lipids in the water-miscible solvent, rate of injection, and effective solvent 94 
removal post-processing. Recent variations on this method include the adoption of inkjet 95 
injection methods (Hauschild et al., 2005). 96 
More recently, microfluidics has been considered for the formulation of liposomes (Jahn et 97 
al., 2007; Kastner et al., 2014; Kastner et al., 2015). The application of microfluidic tools for 98 
liposome manufacturing is based on the theory of a nanoprecipitation reaction resulting from 99 
rapid mixing at the nanolitre scale (Song et al., 2008; deMello, 2006). In contrast to the top-100 
down methods for liposome manufacture, this nanoprecipitation can produce liposomes and 101 
nanoparticles in a one-step process (Bally et al., 2012), with no further disruption of the 102 
resulting liposomes required. The advantages of microfluidic-based technologies include 103 
enhanced control over processing conditions, offering reproducible and robust 104 
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manufacturing of uniform liposome size distributions and, by working at reduced volumes 105 
during development processes, costs can be reduced, whereas throughput is also increased 106 
(Carugo et al., 2016; Jensen, 2001; van Swaay and deMello, 2013; Weibel and Whitesides, 107 
2006).  Furthermore, variations in ﬂow rate and ﬂow rate ratios allows for the engineering of 108 
liposome-based systems in the range of 30 - 80 nm for small interfering RNA (siRNA) delivery 109 
(Belliveau et al., 2012; Zhigaltsev et al., 2012), DNA (Kastner et al., 2014) and low solubility 110 
drugs (Kastner et al., 2015). In the application of microfluidics for liposome manufacture, 111 
there are a range of parameters to be considered (Figure 1) and testing and optimisation of 112 
these parameters is important since they can impact on the critical product attributes of the 113 
liposomal systems (e.g. Kastner et al., 2014). Parameters to be considered range from input 114 
parameters – such as solvent selection, which can be influenced by lipid solubility – to 115 
manufacturing parameters – such as chip design, flow rate of solvents through the chip and 116 
the ratio they are mixed at, whilst temperature may also be a consideration (in the case of 117 
high-transition temperature lipids). In terms of the chip design, micromixers can be classified 118 
into active and passive mixers (Capretto et al., 2011). Passive micromixers require an input 119 
from an external energy source, e.g. pressure-driven, temperature-induced or ultrasonic-120 
driven. In contrast, so called passive mixers do not require an additional external energy 121 
source to achieve mixing, but use the fluid flow and specially designed micro-structures that 122 
enhance diffusion and advection processes (Nguyen and Wu, 2004). In the production of 123 
liposomes, a range of chip designs have been tested, including a staggered herringbone 124 
micromixer based on patterns of grooves in the channel ﬂoor (Figure 1). The design introduces 125 
a chaotic flow in a microchannel by subjecting the fluid to repetitive series of a rotational flow 126 
profile, which is achieved by alteration of the grooves as a function of the axial position in the 127 
channel (Stroock et al., 2002). 128 
Within our laboratories we have already demonstrated the use of microfluidics to formulate 129 
DNA-liposome complexes (Kastner et al., 2014) and incorporate low solubility drugs within 130 
the bilayer of the liposomes (Kastner et al., 2015); however, the passive incorporation of a 131 
hydrophilic drug has yet to be explored. Therefore, the aim of this current research is to build 132 
on this knowledge, and demonstrate the use of microfluidics to prepare sub-100 nm 133 
liposomes incorporating aqueous soluble drugs within their core. Furthermore, this study 134 
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investigate the preparation of liposomes co-entrapping both a hydrophilic and lipophilic drug 135 
within the same formulation to promote co-delivery of drugs.  136 
 137 
2. Materials and methods 138 
2.1. Materials 139 
Egg phosphatidylcholine (PC), 1,2-dimyristoylphosphatidylcholine (DMPC), 1,2-140 
diplmitoylphosphatidylcholine (DPPC), 1,2-disteroylphosphatidylcholine (DSPC) were 141 
purchased from Avanti Polar Lipids, Inc. (Alabaster, AL).  Cholesterol was from Sigma-Aldrich 142 
Company Ltd. (Poole, UK). Glipizide, metformin HCl and Phosphate buffered saline (PBS) in 143 
tablet form (pH 7.4) were purchased from Sigma-Aldrich Company Ltd. (Poole, UK). All the 144 
solvents used in the analysis were of analytical grade and were purchased from Fisher 145 
Scientific UK (Loughborough, UK). Water used in the process of liposome preparation was of 146 
milli-Q grade.   147 
 148 
2.2. Preparation of liposomes using microfluidics 149 
To prepare liposomes, the NanoAssemblrTM benchtop (Precision Nanosystems, Agronomy Rd, 150 
Vancouver) was used with a 300 micron Staggered Herringbone Micromixer. Briefly, the lipids 151 
at the appropriate ratio were dissolved in methanol. The aqueous buffer used in all studies 152 
was PBS, 10 mM, pH 7.4. The flow rate ratio (FRR) between the aqueous and solvent stream 153 
was varied from 5:1 to 1:1 (aq:solvent ratio) and the total flow rate (TFR) was varied from 5 154 
to 15 mL/min. Through this method, liposome formation and incorporation of the drug(s) can 155 
be performed simultaneously by addition of the drug into the appropriate phase; within these 156 
studies, glipizide was dissolved in the solvent phase (1.1 mg/mL), whilst metformin was 157 
dissolved in PBS prior to microfluidic mixing. The liposome formulations were collected from 158 
the chamber outlet and dialysed at room temperature against PBS buffer for removal of 159 
residual solvent and non-loaded drug.  160 
 161 
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2.3. Liposome characterisation 162 
Dynamic light scattering (DLS) was used to determine the size, reported as Z-average (based 163 
on intensity), and polydispersity index (PDI) of liposomes using Malvern NanoZS (Malvern 164 
Instruments, Worcestershire, UK). Particle size was measured in PBS diluted 1 in 300, pH 7.4, 165 
25 ⁰C. The zeta potential was also measured using the Malvern NanoZS; based on the particle 166 
electrophoresis principle in PBS, 1 mM, pH 7.4, 25 ⁰C. 167 
 168 
2.4. Removal of solvent and non-incorporated drug   169 
3500-dalton dialysis tubing (Medicell membranes Ltd, London, UK) was used to remove 170 
residual solvent and non-entrapped drug from the liposomal suspension. Prior to use, the 171 
dialysis tubing was soaked under running water for two hours. Dialysis was performed using 172 
PBS (composition: phosphate buffer 0.01 M, 0.0027 M potassium chloride and 0.137 M 173 
sodium chloride, pH 7.4). 174 
 175 
2.5. Quantification of lipid recovery  176 
HPLC- ELSD (high performance liquid chromatography- evaporative light scattering detector) 177 
was used to quantify the lipid recovery of liposomes produced by microfluidics at a 3:1 FRR 178 
and 15 mL/min TFR. A Luna column (C18(2), 5 µm, dimensions 4.60 X 150 mm, pore size 100 179 
Å) from Phenomenex (Macclesfield, UK) was used to detect the lipids. A 2 mL/min flow rate 180 
was used with a twenty minute elution gradient, composed of solvent A (0.1% TFA in water) 181 
and solvent B (100% methanol). During the first six minutes the gradient was 15:85 (A:B), at 182 
6.1 minutes 0: 100 (A:B) and then back to the initial gradient of 15: 85 (A:B) from 15.1 to 20 183 
minutes. The phospholipid and cholesterol lipids were analysed within the same run as they 184 
have different elution times. The lipid recovery was calculated as a percentage in comparison 185 
to the initial concentration of the stock solution. 186 
 187 
2.6. Quantification of non-entrapped and entrapped drugs 188 
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Simultaneous quantification of metformin and glipizide (both liposome entrapped and non-189 
entrapped) was performed using reversed-phase high performance liquid chromatography 190 
(RP-HPLC, Shimadzu 2010-HT, Milton Keynes, UK) connected with an ultra-violet detector at 191 
233 nm to allow simultaneous quantification of both drugs. Isocratic elution was performed 192 
using mobile phase of acetonitrile:PBS (65:35, pH 5.75) at constant flow rate of 1.0 193 
mL/minute, using a Luna column (C-18, 5µ, i.d. 150 X 4.6 mm) from Phenomenex 194 
(Macclesfield, UK). A calibration curve produced from linear standards was used as reference 195 
for the quantification of unknown. The calibration curved reported linearity (R²) >0.995 and 196 
all measurements were within the level of detection and level of quantification. Drug 197 
incorporation is reported as % of initial amount used, and in all instances, overall recovery of 198 
both drugs was also determined from amount entrapped and non-entrapped drug and was 199 
between 90 to 110%.  200 
 201 
2.7. Drug release study 202 
The CE7smart USP-4 system (SOTAX AG, Switzerland) was used to create an incubating 203 
environment for the release of drug encapsulated within liposomes. PBS (pH 7.4) was used in 204 
a closed loop system and was circulated at constant temperature (37 ± 1°C) at a constant flow 205 
of 8.0 mL/minute. Samples were withdrawn at time intervals of 10, 30, 60, 90, 120, 180, 360, 206 
540, 720 and 1440 minutes. Drug release was quantified using RP-HPLC (described in section 207 
2.6.) and reported as % release relative to amount of drug entrapped within liposomes. 208 
 209 
2.8. Cryo-TEM imaging of liposomes 210 
All the samples were freshly prepared on the day of analysis. Empty, single and co-drug loaded 211 
liposomes were prepared using the method described before (section 2.2). A 3 µl aliquot of 212 
each sample was placed onto a pre-cleaned lacey carbon coated grid and flash frozen by 213 
plunging into liquid ethane cooled by liquid nitrogen. Samples were stored in liquid nitrogen 214 
and conveyed to a cryo-holder and observed under the electron microscope at liquid nitrogen 215 
temperatures. Grids were observed using Tecnai 12 G2 electron microscope (FEI, Eindhoven) 216 
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at 80 kV and the evaluation was performed in the magnification range of 40000 X to 135000 217 
X. 218 
 219 
2.9. Statistical tools 220 
Unless stated otherwise, the results were calculated as mean ± standard deviation (SD). 221 
ANOVA followed by Tukey post hoc analysis was performed for comparison and significance 222 
was acknowledged for p values less than 0.05. All the calculations were made using Graphpad 223 
version-6 (GraphPad Inc., La Jolla, CA). 224 
 225 
3. Results 226 
3.1 Solvent selection and lipid concentrations in the manufacture of liposomes using 227 
microfluidics 228 
When establishing the process of liposome manufacture using microfluidics, one of the initial 229 
input parameters to consider is the solvent selection. For appropriate mixing to occur, the 230 
solvent needs to be miscible with the aqueous phase. Other factors dictating this solvent 231 
selection are the lipid and drug compatibility and solubility in the selected solvent and 232 
aqueous phase. To consider the effect of solvent selection, initial studies investigated the 233 
preparation of 4 liposome formulations based on PC, DMPC. DPPC or DSPC mixed with 234 
equimolar cholesterol (2:1 mass ratio). Results in Figure 2 demonstrate that solvent selection 235 
plays an important role in the size of the formed vesicles; the combination of using methanol 236 
for the lipid solvent and PBS as the aqueous phase produces liposomes in the smallest size 237 
range, irrespective of the phospholipid used, with liposomes being approximately 70 to 100 238 
nm in size. Replacement of methanol with ethanol in combination with PBS made no notable 239 
difference to liposome size in the case of PC, DMPC or DPPC liposomes. However, in the case 240 
of the DSPC:chol liposomes, preparing these vesicles using PBS and ethanol as the initial 241 
solvents results in significantly (p<0.05) larger vesicles that were well over 1000 nm in size. 242 
Indeed, the DSPC formulation in general tended to be more sensitive to the initial solvent 243 
selection, as switching from PBS to Tris buffer in combination with methanol also increased 244 
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the size of the DSPC:chol liposomes from 69 ± 3 nm to over 405 ± 63 nm (Figure 2). In general, 245 
the polydispersity of the liposome formulation (as measured by the PDI) followed a similar 246 
trend to the vesicle size, with the combination of methanol with PBS giving the most 247 
homogeneous preparations. 248 
The initial lipid amount in the solvent stream is also an important consideration in the 249 
production of liposomes using microfluidics, with lower levels of lipids tending to promote 250 
larger vesicles, as shown in Figure 3. However, working with initial amounts of lipid above 1 251 
mg (3 mg/mL) produced vesicles around 100 nm or less with good lipid recovery (Figure 3) 252 
and, irrespective of the lipid concentrations, varying the flow rate had no significant impact 253 
on vesicle size (results not shown).  254 
 255 
3.2 Selection of flow rate and solvent to aqueous flow rate ratio 256 
Upon selection of the two base solvents (methanol with PBS), the next stage in the process 257 
was to identify the effect of both the aqueous: solvent media (PBS:methanol) mixing ratio and 258 
also the total flow rate; therefore, the flow rate ratio was varied from 1:1 through to 5:1 and 259 
the total flow rate was varied from 5 to 15 mL per minute and the effect on the liposomal 260 
attributes (size, PDI and zeta potential) were investigated. Given that these liposomes were 261 
to be loaded with both an aqueous soluble drug (metformin) and a bilayer loaded drug 262 
(glipizide), DSPC was selected as the phospholipid based on previous studies that 263 
demonstrated longer chain lipids offer greater capacity to load drug within the bilayer of 264 
vesicles (Mohammed et al., 2004; Ali et al., 2010; Ali et al., 2013) and retain drug within the 265 
aqueous core (Gregoriadis and Davis, 1979). The cholesterol content was also reduced given 266 
that a range of previous studies have shown that cholesterol is known to reduce aqueous 267 
soluble drug leakage across the lipid bilayer (e.g. (Briuglia et al., 2015)), but also to potentially 268 
inhibit drug incorporation in the liposomal bilayer (Ali et al., 2010; Mohammed et al., 2004). 269 
Therefore, a DSPC: chol lipid weight ratio of 10:4 was selected to meet the needs of both good 270 
aqueous drug retention and bilayer drug loading.  271 
Results in Figure 4 demonstrate that a low aqueous:solvent ratio of 1:1 tended to produce 272 
the largest vesicles, irrespective of the total flow rate, with liposomes being approximately 273 
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200 to 300 nm in size with PDI values of between 0.38 to 0.67. However, an increase in the 274 
aqueous to solvent ratio to 3:1 reduced the vesicle sizes to approximately 120 – 130 nm, and 275 
a further increase in the ratio to 5:1 reduced the vesicle size range to 80 to 90 nm with a PDI 276 
range of 0.11 to 0.22, again with no notable effect of total flow rate being seen (Figure 4).  In 277 
all cases, the liposome formulations were near neutral in zeta potential as would be expected 278 
for such formulations. From these studies, it can be seen that, across the range tested, the 279 
flow rate ratio but not total flow rate had an impact on vesicle size; therefore, further studies 280 
adopted a solvent to aqueous ratio of 5:1.  281 
 282 
3.3 Incorporation of aqueous and bilayer drug loading within liposomes manufactured by 283 
microfluidics 284 
To investigate drug loading within both the aqueous and bilayer phases of liposomes, 285 
metformin and glipizide were selected as model drugs, given their contrasting solubility and 286 
their combined use in treating type-2 diabetes. In terms of initial drug added, 300 µg of 287 
glipizide dissolved in methanol (the maximal amount soluble in the solvent phase used; 0.27 288 
mL) along with the DSPC and cholesterol (2.7 mg and 1.1 mg, respectively), and 20 mg of 289 
metformin was added to the PBS phase. Results in Figure 5 show that drug loading of glipizide 290 
within the liposomal bilayer was approximately 40% and metformin entrapment was 291 
approximately 20%. Furthermore, the results show that loading of the drug individually or in 292 
combination had no significant impact on the loading capacity of the liposomes. However, the 293 
presence of either drug in the formulation tended to push the vesicle size down by 294 
approximately 20 nm, with the measured z-average particle size being 50 to 60 nm. The 295 
bilayer vesicle constructs with and without the addition of these drugs as imaged by cryo-TEM 296 
are shown in Figure 6; in all 4 cases, the formulations show a high proportion of small 297 
unilamellar vesicles around 60 to 80 nm in size.  298 
The effect of drug co-loading within the liposomal system on their relative release profiles 299 
was also investigated (Figure 7). The majority of the in-vitro drug release studies are based 300 
upon dialysis of liposomal formulation against large volumes of buffers or other simulated 301 
media at physiological temperatures, and this excess buffer can lead to un-realistic gradients 302 
across the liposomal membranes. Therefore, drug release was studied using USP-4 (flow 303 
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through cell (FTC) method), which has proved to be very versatile, with advantages of 304 
operating ρH gradients, achieving sink conditions for sparingly soluble drugs by use of 305 
unlimited media volume and, most importantly for the current study, appropriateness for 306 
micro-sized dosage forms, as it obviates sample aggregation.  FTC enables dissolution 307 
conditions to be achieved that are more representative of physiological conditions by 308 
choosing the right flow rates, media type, media volume and cell preparation. Furthermore, 309 
FTC is the most discriminating between formulation variants (Qureshi, S.A., 2006), whilst in 310 
the closed loop system configuration, the dissolution media is re-circulated through the 311 
sample contained in a flow through cell, producing a cumulative curve progression, with the 312 
added advantage of a small volume in which dissolution takes place; the 22.6 mm-cell without 313 
glass beads provides 19 mL capacity (Brown, W. 2005). The results show that, in both cases, 314 
the drug incorporated individually had a slower release rate profile compared to the 315 
liposomes containing both metformin and glipizide.  For example, after 1 hour, liposomes 316 
containing glipizide released 3% of the bilayer loaded glipizide; however, when metformin 317 
was also present within the liposome formulation, glipizide release increased to 12%. 318 
Similarly, after 1 hour metformin release increased from 35% to 64% when glipizide was 319 
present in the bilayer (Figure 7), suggesting that co-loading of both drugs on the system had 320 
an impact on the structural attributes of the liposomes.  321 
 322 
4. Discussion 323 
The use of microfluidics for the scalable production of liposomes allows for the cost-effective 324 
and rapid production of liposomes. Despite increased research in exploring different 325 
microfluidics parameters on liposome size, the effect of the organic solvent (used to dissolve 326 
lipids) on liposome size has not been fully explored. During this microfluidics-based 327 
manufacturing process, it has been proposed that the liposomes form as a result of the 328 
alcohol and aqueous buffer mixing, thereby increasing the polarity of the solvent. This in turn 329 
progressively decreases the lipid solubility, thereby promoting self-assembly into planar lipid 330 
bilayers. As these planar bilayer discs grow, the surface area of hydrophobic chains exposed 331 
to polar solvent around the perimeter of the disc will grow and increase the interfacial 332 
tension. To circumvent this, the discs will bend and eventually close into spherical vesicles. 333 
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Most commonly, isopropyl alcohol has been used to dissolve lipids, with some studies using 334 
the less toxic solvent, ethanol (Carugo et al., 2016). As shown in figure 2, despite all four lipids 335 
being soluble in both methanol and ethanol, the organic solvent of choice affects the 336 
liposome size attributes, potentially due to the differences in the self-assembly 337 
rates/configurations of the discs and resultant vesicles. Previous investigations into use of 338 
microfluidics to prepare liposomes (Zook and Vreeland, 2010) have shown that vesicle size is 339 
modulated by temperature in the case of high-transition temperature lipids. The authors note 340 
this to be due to the high membrane elasticity modulus associated with high transition 341 
temperature lipids, with liposomes formed below or near the transition temperature of the 342 
lipids tending to be larger. In contrast, liposomes formed at a temperature far above the 343 
transition temperature have a much smaller dependence of size, where the membrane 344 
elasticity modulus is relatively constant (Zook and Vreeland, 2010). Therefore, whilst 345 
cholesterol is present in the formulations and could nullify the impact of the DSPC transition 346 
temperature, during nanoprecipitation and formation of liposomes, these transition 347 
temperatures may have an impact.  348 
An additional issue with the use of ethanol may be that the residual presence of ethanol in 349 
the liposome suspensions may also promote vesicle fusion; previous studies have shown that 350 
increased ethanol concentration causes aggregation of liposomes produced by microfluidics 351 
at a 1:1 FRR, and increasing the FRR to 3:1 removed the aggregation problem and formed 352 
smaller liposomes (Maeki et al., 2015). Furthermore, the increased vesicle size may be a result 353 
of the residual ethanol that may accumulate at the organic and aqueous interface (Patra et 354 
al., 2006) thereby promoting vesicle fusion. Using computational studies to explore the effect 355 
of methanol and ethanol on the DPPC lipid bilayer, Patra et al (2006) showed that ethanol 356 
affects the structural properties of liposome bilayers, with this effect possibly more 357 
prominent with the DSPC formulation due to the longer alkyl chains.  358 
The results in Figure 4 show that manipulating flow conditions such as the speed at which 359 
both streams, aqueous and organic, pass through the channels (TFR) did not affect the size of 360 
the liposomes. On the other hand, the ratio between aqueous and organic phases (FRR) has 361 
shown to be a key parameter in the control of the liposome size. This could be explained due 362 
to the increase of aqueous volume that favours the formation of liposomes, since the lipid in 363 
solvent is diluted (Jahn et al., 2004; Zook and Vreeland, 2010).  Therefore, increasing FRR 364 
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produces a dilution effect, reducing amount of solvent (methanol in our case), and a faster 365 
mixing. By this means the formation of larger liposomes by particle fusion and lipid exchange 366 
is reduced (Zhigaltsev et al., 2012). In contrast, at low FRRs, the organic solvent is injected 367 
into the system more slowly, allowing more time for both streams to interact, and therefore, 368 
producing larger liposomes (Zhigaltsev et al., 2012). These results show that control of the 369 
flow rate ratio can control vesicle size and that the rate of liposome production (in terms of 370 
total flow rate) may be increased without impact on the liposome attributes. 371 
In terms of drug loading within these vesicles prepared using microfluidics, the loading was 372 
based on the principle of passive loading, where both drug and lipids are co-dispersed in the 373 
aqueous phase. Generally, encapsulation efficiency for passive loading is less than 10% (Cullis 374 
et al., 1989), whilst within our studies, we achieve notably higher hydrophilic (metformin) 375 
drug loading of approximately 20% (Figure 5). The use of microfluidics has been suggested to 376 
improve hydrophilic loading; For example, Jahn et al., 2008 reported unexpectedly high 377 
entrapment efficiencies of a hydrophilic moiety (sulforhodamine B dissolved in PBS) within 378 
nanometer-scale liposomes prepared using a continuous-flow microfluidics system. The 379 
authors suggest that the high encapsulation efficiency may be due to a spatial concentration 380 
enhancement induced by viscosity anisotropy in the microchannel (Jahn et al., 2008). In terms 381 
of bilayer loading, the simultaneous packaging of the lipids and glipizide within the bilayer can 382 
promote drug loading of approximately 40%, similar to our previous studies with propofol 383 
(Kastner et al., 2015). The small decrease in size noted when liposomes were formed in the 384 
presence of metformin and/or glipizide may be a result of changes in viscosity, miscibility 385 
and/or mixing at the interphase as the liposomes form as discussed by Jan et al. (2008). 386 
In terms of drug release, when both types of drugs are co-entrapped, our studies 387 
demonstrated that they release faster than when individually encapsulated, suggesting an 388 
interference or synergistic effect occurs. We hypothesised that the presence of glipizide 389 
within the liposomal bilayer may interfere with the packing density of the lipids in the small 390 
and highly curved bilayers and thereby increasing bilayer drug permeability. Furthermore, the 391 
presence of metformin within the liposomes may also induce a concentration gradient across 392 
the membrane, further driving the disruption of the bilayer, thereby simultaneously 393 
increasing the release of both drugs.  394 
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 395 
5. Conclusions 396 
Our results provide a concise analysis of liposome manufacturing using microfluidics. 397 
Furthermore, for the first time we demonstrate the simultaneous entrapment of a hydrophilic 398 
and a lipophilic drug (metformin and glipizide) using a scalable microfluidics system. Our 399 
results demonstrate that microfluidics promotes greater hydrophilic and hydrophilic drug 400 
loading compared to traditional methods, whilst critical factors to consider in the 401 
manufacture of liposomes using microfluidics include the choice of solvent, lipid 402 
concentration, and the flow rate ratio adopted during the microfluidics process. Therefore, it 403 
can be concluded that microfluidics is a good alternative for liposome manufacturing. 404 
 405 
6. Acknowledgements 406 
This work was part funded by Aston University (SJ), the EPSRC Centre for Innovative 407 
Manufacturing in emergent macromolecular therapies (EP/L015218/1) (MH) and 408 
EP/I033270/1 (EK) and EU Horizon 2020 project TBVAC 2020 (Grant no. 643381) (CBR). 409 
 410 
Supporting information Available: Data presented in this publication can be found at [DOI 411 
XXXXXXXXXXXX to be provided at proofing stage].  412 
16 
 
References 413 
Ali, M.H., Kirby, D.J., Mohammed, A.R., Perrie, Y., 2010. Solubilisation of drugs within liposomal 414 
bilayers: alternatives to cholesterol as a membrane stabilising agent. Journal of Pharmacy and 415 
Pharmacology 62, 1646-1655. 416 
Almeida, J., Edwards, D.C., Brand, C., Heath, T., 1975. Originally published as Volume 2, Issue 417 
7941FORMATION OF VIROSOMES FROM INFLUENZA SUBUNITS AND LIPOSOMES. The Lancet 306, 418 
899-901. 419 
Azmin, M.N., Florence, A.T., Handjani-Vila, R.M., Stuart, J.F.B., Vanlerberghe, G., Whittaker, J.S., 420 
1985. The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and 421 
distribution of methotrexate in mice. Journal of Pharmacy and Pharmacology 37, 237-242. 422 
Baillie, A.J., Florence, A.T., Hume, L.R., Muirhead, G.T., Rogerson, A., 1985. The preparation and 423 
properties of niosomes—non-ionic surfactant vesicles. Journal of Pharmacy and Pharmacology 37, 424 
863-868. 425 
Bally, F., Garg, D.K., Serra, C.A., Hoarau, Y., Anton, N., Brochon, C., Parida, D., Vandamme, T., 426 
Hadziioannou, G., 2012. Improved size-tunable preparation of polymeric nanoparticles by 427 
microfluidic nanoprecipitation. Polymer 53, 5045-5051. 428 
Bangham, A.D., Horne, R.W., 1964. Negative staining of phospholipids and their structural 429 
modification by surface-active agents as observed in the electron microscope. Journal of Molecular 430 
Biology 8, 660-IN610. 431 
Batzri, S., Korn, E.D., 1973. Single bilayer liposomes prepared without sonication. Biochimica et 432 
Biophysica Acta (BBA) - Biomembranes 298, 1015-1019. 433 
Belliveau, N.M., Huft, J., Lin, P.J.C., Chen, S., Leung, A.K.K., Leaver, T.J., Wild, A.W., Lee, J.B., Taylor, 434 
R.J., Tam, Y.K., Hansen, C.L., Cullis, P.R., 2012. Microfluidic Synthesis of Highly Potent Limit-size Lipid 435 
Nanoparticles for In Vivo Delivery of siRNA. Molecular Therapy. Nucleic Acids 1, e37. 436 
Briuglia, M.-L., Rotella, C., McFarlane, A., Lamprou, D.A., 2015. Influence of cholesterol on liposome 437 
stability and on in vitro drug release. Drug delivery and translational research 5, 231-242. 438 
Capretto, L., Cheng, W., Hill, M., Zhang, X., 2011. Micromixing Within Microfluidic Devices, in: Lin, B. 439 
(Ed.), Microfluidics: Technologies and Applications. Springer Berlin Heidelberg, Berlin, Heidelberg, 440 
pp. 27-68. 441 
Carugo, D., Bottaro, E., Owen, J., Stride, E., Nastruzzi, C., 2016. Liposome production by microfluidics: 442 
potential and limiting factors. Scientific Reports 6, 25876. 443 
Conacher, M., Alexander, J., Brewer, J.M., 2001. Oral immunisation with peptide and protein 444 
antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine 19, 2965-2974. 445 
Cullis, P., Mayer, L., Bally, M., Madden, T., Hope, M., 1989. Generating and loading of liposomal 446 
systems for drug-delivery applications. Advanced drug delivery reviews 3, 267-282. 447 
deMello, A.J., 2006. Control and detection of chemical reactions in microfluidic systems. Nature 442, 448 
394-402. 449 
Felgner, P.L., Gadek, T.R., Holm, M., Roman, R., Chan, H.W., Wenz, M., Northrop, J.P., Ringold, G.M., 450 
Danielsen, M., 1987. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. 451 
Proceedings of the National Academy of Sciences of the United States of America 84, 7413-7417. 452 
Gregoriadis, G., Davis, C., 1979. Stability of liposomes invivo and invitro is promoted by their 453 
cholesterol content and the presence of blood cells. Biochemical and Biophysical Research 454 
Communications 89, 1287-1293. 455 
Gregoriadis, G., Ryman, B.E., 1971. Liposomes as carriers of enzymes or drugs: a new approach to 456 
the treatment of storage diseases. Biochemical Journal 124, 58P. 457 
Hauschild, S., Lipprandt, U., Rumplecker, A., Borchert, U., Rank, A., Schubert, R., Förster, S., 2005. 458 
Direct Preparation and Loading of Lipid and Polymer Vesicles Using Inkjets. Small 1, 1177-1180. 459 
Jahn, A., Reiner, J., Vreeland, W., DeVoe, D., Locascio, L., Gaitan, M., 2008. UNEXPECTEDLY HIGH 460 
ENTRAPMENT EFFI-CIENCIES IN NANOMETER SCALE LIPOSOMES WITH HYDRODYNAMIC FOCUSING 461 
17 
 
USING CONTINUOUS-FLOW MICROFLUIDICS, Twelfth International Conference on Miniaturized 462 
Systems for Chemistry and Life Sciences. 463 
Jahn, A., Vreeland, W.N., DeVoe, D.L., Locascio, L.E., Gaitan, M., 2007. Microfluidic directed 464 
formation of liposomes of controlled size. Langmuir 23, 6289-6293. 465 
Jahn, A., Vreeland, W.N., Gaitan, M., Locascio, L.E., 2004. Controlled vesicle self-assembly in 466 
microfluidic channels with hydrodynamic focusing. Journal of the American Chemical Society 126, 467 
2674-2675. 468 
Jensen, K.F., 2001. Microreaction engineering—is small better? Chemical Engineering Science 56, 469 
293-303. 470 
Kastner, E., Kaur, R., Lowry, D., Moghaddam, B., Wilkinson, A., Perrie, Y., 2014. High-throughput 471 
manufacturing of size-tuned liposomes by a new microfluidics method using enhanced statistical 472 
tools for characterization. International Journal of Pharmaceutics 477, 361-368. 473 
Kastner, E., Verma, V., Lowry, D., Perrie, Y., 2015. Microfluidic-controlled manufacture of liposomes 474 
for the solubilisation of a poorly water soluble drug. Int J Pharm 485, 122-130. 475 
Kumar, G.P., Rajeshwarrao, P., 2011. Nonionic surfactant vesicular systems for effective drug 476 
delivery—an overview. Acta Pharmaceutica Sinica B 1, 208-219. 477 
Maeki, M., Saito, T., Sato, Y., Yasui, T., Kaji, N., Ishida, A., Tani, H., Baba, Y., Harashima, H., Tokeshi, 478 
M., 2015. A strategy for synthesis of lipid nanoparticles using microfluidic devices with a mixer 479 
structure. RSC Advances 5, 46181-46185. 480 
Mohammed, A., Weston, N., Coombes, A., Fitzgerald, M., Perrie, Y., 2004. Liposome formulation of 481 
poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability. International 482 
journal of pharmaceutics 285, 23-34. 483 
Nguyen, N.-T., Wu, Z., 2004. Micromixers—a review. Journal of Micromechanics and 484 
Microengineering 15, R1. 485 
Okada, J.i., Cohen, S., Langer, R., 1995. In Vitro Evaluation of Polymerized Liposomes as an Oral Drug 486 
Delivery System. Pharmaceutical Research 12, 576-582. 487 
Patra, M., Salonen, E., Terama, E., Vattulainen, I., Faller, R., Lee, B.W., Holopainen, J., Karttunen, M., 488 
2006. Under the Influence of Alcohol: The Effect of Ethanol and Methanol on Lipid Bilayers. 489 
Biophysical Journal 90, 1121-1135. 490 
Pons, M., Foradada, M., Estelrich, J., 1993. Liposomes obtained by the ethanol injection method. 491 
International Journal of Pharmaceutics 95, 51-56. 492 
Song, Y., Hormes, J., Kumar, C.S.S.R., 2008. Microfluidic Synthesis of Nanomaterials. Small 4, 698-493 
711. 494 
Stroock, A.D., Dertinger, S.K.W., Ajdari, A., Mezić, I., Stone, H.A., Whitesides, G.M., 2002. Chaotic 495 
Mixer for Microchannels. Science 295, 647-651. 496 
Uchegbu I.F., Florence, A.T., 1995. Non-ionic surfactant vesicles (niosomes): physical and 497 
pharmceutical chemistry. Adv Colloid Interface Sci, 58, 1-55. 498 
van Swaay, D., deMello, A., 2013. Microfluidic methods for forming liposomes. Lab on a Chip 13, 499 
752-767. 500 
Weibel, D.B., Whitesides, G.M., 2006. Applications of microfluidics in chemical biology. Current 501 
Opinion in Chemical Biology 10, 584-591. 502 
Zhigaltsev, I.V., Belliveau, N., Hafez, I., Leung, A.K.K., Huft, J., Hansen, C., Cullis, P.R., 2012. Bottom-503 
Up Design and Synthesis of Limit Size Lipid Nanoparticle Systems with Aqueous and Triglyceride 504 
Cores Using Millisecond Microfluidic Mixing. Langmuir 28, 3633-3640. 505 
Zook, J.M., Vreeland, W.N., 2010. Effects of temperature, acyl chain length, and flow-rate ratio on 506 
liposome formation and size in a microfluidic hydrodynamic focusing device. Soft Matter 6, 1352-507 
1360. 508 
 509 
  510 
18 
 
Figure legends 511 
512 
Figure 1: Liposomes produced by microfluidics – process and formulation conditions. In the 513 
production of liposomes using microfluidics, the lipids and lipophilic drugs are dissolved in 514 
an appropriate solvent and mixed with an aqueous phase containing water soluble drugs. 515 
These are mixed using micromixers that are available in a range of designs. Within these 516 
studies, a staggered herringbone micromixer was used. The rate of mixing of the aqueous 517 
and solvent buffer and the total follow rate are also parameters that require optimisation 518 
and the lipid concentration and lipid transition temperature may impact on this 519 
optimisation process. In terms of critical product attributes, key factors to consider include 520 
the liposome physico-chemical attributes (including size, pdi, zeta potential), drug loading 521 
and drug release profiles and lipid recovery. 522 
19 
 
523 
Figure 2: The effect of solvent and buffer selection on liposomes prepared by microfluidics. 524 
Liposomes composed of PC, DMPC, DPPC, DSPC and cholesterol (1:1 molar ratio/2:1 mass 525 
ratio) were prepared by microfluidics at a 3:1 Flow rate ratio and 15 mL/ min Total Flow 526 
rate. Lipids were either dissolved in ethanol or methanol. Tris buffer or PBS were used as 527 
the aqueous phase, with size and PDI measured. Results are expressed as the means of 528 
three independent experiments ± SD. 529 
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530 
Figure 3: Consideration of A) initial lipid amount and B) lipid recovery. Liposomes composed 531 
of PC and cholesterol (1:1 molar ratio/2:1 mass ratio) were prepared by microfluidics at a 532 
3:1 flow rate ratio using increasing amounts of initial total lipid, with size with size and PDI 533 
measured. Results are expressed as the means of three independent experiments ± SD. For 534 
lipid recovery, results are averaged across a range of PC, DMPC, DPPC and DSPC in 535 
equimolar concentration with cholesterol. Results are expressed as the means of at least 536 
three independent experiments ± SD. 537 
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538 
Figure  4: The effect on flow rate ratio and total flow rate on the liposomes z-average 539 
diameter, PDI and zeta potential of DSPC:cholesterol liposomes.  Results represent mean ± 540 
SD, n  = 4. 541 
 542 
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543 
Figure  5: A comparison of DSPC:cholesterol liposomes z-average diameter, PDI and drug 544 
loading for small unilamellar liposomes with glipizide loading within the bilayer, with 545 
metformin loading within the aqueous phase, liposomes containing both glipizide and 546 
metformin and liposomes without drug present.  Results represent mean ± SD, n  = 4. 547 
 548 
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549 
Figure  6:  DSPC:Cholesterol liposomes produced by microfluidics at a 5:1 flow rate ratio and 550 
15 mL/min and imaged using cryo-TEM. A) Liposomes without drug incorporated, B) 551 
liposomes with glipizide loading within the bilayer, C) liposomes with metformin loading 552 
within the aqueous phase D) liposomes containing both glipizide and metformin. The size bar 553 
represents 500 nm. 554 
 555 
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556 
Figure 7: Drug release profiles, measured using USP IV, from liposomes incorporating 557 
glipizide or metformin individually, or co-encapsulated within DSPC:chol liposome 558 
formulations produced via microfluidics as outlined in Figure 5. Release studies were 559 
undertaken with PBS (pH=7.4), temperature 37 ⁰C and drug concentrations quantified by 560 
RP-HPLC. Results represent mean ± SD, n  =  4. 561 
